

01st
& 02nd
OCTOBER
2026

15th ANNUAL ACUTE LEUKEMIA MEETING

IN PERSON & VIRTUAL EVENT

DIRECTOR

Dr. Adolfo de la Fuente

MD Anderson Cancer Center Madrid - Hospiten, España

Organized by

15th

ANNUAL
ACUTE

LEUKEMIA
MEETING

IN PERSON
& VIRTUAL
EVENT

SCIENTIFIC COMMITTEE

- Dr. Ana Alfonso, *Clínica Universidad de Navarra. Pamplona, Spain*
Dr. Claudia Núñez-Torrón, *Hospital Universitario Infanta Sofía. Madrid, Spain*
Dr. Carlos Jiménez-Chillón, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*
Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa. Zaragoza, Spain*
Dr. Ángela Figuera, *Hospital de La Princesa. Madrid, Spain*
Dr. Alessandro Isidori, *Marche Nord Hospital. Pesaro, Italy*
Dr. Jordi Esteve, *Hospital Clinic de Barcelona, Spain*
Dr. Joaquín Sánchez, *Hospital Universitario Reina Sofía. Córdoba, Spain*
Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*
Dr. Valentín García-Gutiérrez, *Hospital Universitario Ramón y Cajal. Madrid, Spain*
Dr. Guillermo García-Manero, *MD Anderson Cancer Center. Houston, USA*

AMBASSADORS

- Dr. María Marta Rivas, *Hospital Universitario Austral. Buenos Aires, Argentina*
Dr. Isolda Fernández, *Centro de Hematología Pavlovsky. Buenos Aires, Argentina*
Dr. Virginia Abello, *Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center. Bogotá, Colombia*
Dr. Claudia Sossa, *Complejo Médico Fundación Oftalmológica de Santander - Clínica Carlos Ardila Lulle (FOSCAL). Bucaramanga, Colombia*
Dr. Mónica Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente. Concepción, Chile*
Dr. Carlos Plaza, *UEES Clinic y SOLCA. Guayaquil, Ecuador*
Dr. Breno Moreno de Gusmão, *Beneficência Portuguesa de São Paulo. Brasil*
Dr. Gilberto Barranco, *Hospital General de México, Mexico City*
Dr. Margarida Coucelo, *Unidade Local de Saúde de Coimbra, Portugal*
Dr. Joana Brioso Infante, *Centro Hospitalar Universitário de Lisboa Norte, Portugal*
Dr. Anne Louise Tølbøll Sørensen, *Rigshospitalet Copenhagen University. Copenhagen, Denmark*
Dr. Mika Kontro, *University of Helsinki, Finland*

Thursday, 1st of October, 2026

09:30 - 09:40

Introduction and welcome

09:40 - 10:55

SESSION 1

Anemia as a clinical problem, its impact on quality of life, and its role as a prognostic factor

Chairs:

Dr. Valentín García Gutiérrez, *Hospital Universitario Ramón y Cajal. Madrid, Spain*

Dr. Gilberto Barranco, *Hospital General de México. Mexico City*

Dr. Carlos Plaza, *UEES Clinic y SOLCA. Guayaquil, Ecuador*

PART 1 | Myelofibrosis: what are new drugs contributing to clinical practice?

09:40 - 10:00

Redefining the treatment algorithm for myelofibrosis

Dr. Blanca Xicoy, *ICO - Hospital Germans Trias i Pujol. Barcelona, Spain*

10:00 - 10:20

The challenge of new treatments for myelofibrosis

Dr. Valentín García Gutiérrez, *Hospital Universitario Ramón y Cajal. Madrid, Spain*

10:20 - 10:40

Targeting mutated CALR in myelofibrosis: from molecular biology to clinical application

Dr. Gonzalo Carreño, *Hospital Universitario 12 de Octubre. Madrid, Spain*

10:40 - 10:55

Discussion

10:55 - 11:25

Coffe break

11:25 - 12:00

SESSION 1

Anemia as a clinical problem, its impact on quality of life, and its role as a prognostic factor

Chairs:

Dr. Ana Alfonso, *Clínica Universidad de Navarra. Pamplona, Spain*

Dr. Isolda Fernández, *Centro de Hematología Pavlovsky. Buenos Aires, Argentina*

PART 2 | Low-Risk MDS

11:25 - 11:45

Lower-risk MDS therapy: moving beyond quality of life toward overall survival

Dr. Guillermo García-Manero, *MD Anderson Cancer Center. Houston, USA*

11:45 - 12:00

Discussion

15th

ANNUAL
ACUTE

LEUKEMIA
MEETING

IN PERSON
& VIRTUAL
EVENT

12:00 - 13:35

SESSION 2

Immunotherapy

Chairs:

Dr. Alessandro Isidori, *Marche Nord Hospital. Pesaro, Italy*

Dr. Jordi Esteve, *Hospital Clinic de Barcelona, Spain*

Dr. Joana Brioso Infante, *Centro Hospitalar Universitário de Lisboa Norte, Portugal*

12:00 - 12:20

Cellular therapy platforms in acute myeloid leukemias: where are we now and where are we going?

Dr. Marion Subklewe, *Ludwig-Maximilians-Universität München, Germany*

12:20 - 12:40

Is it time for CAR-T therapy in AML?

Dr. Nela Klein-González, *Hospital Clinic de Barcelona – IDIBAPS, Spain*

12:40 - 13:00

Next generation CD19 CD3 bispecifics

Dr. Alba Puyuelo, *Hospital Universitario Vall d'Hebron. Barcelona, Spain*

13:00 - 13:20

Pivекimab

Dr. Naval Daver, *MD Anderson Cancer Center. Houston, USA*

13:20 - 13:35

Discussion

13:35 - 14:40

Lunch

13:35 - 14:15

Lunch Session

Mastocytosis

Chairs:

Dr. Carlos Jiménez-Chillón, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid-Hospiten. Madrid, Spain*

Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa. Zaragoza, Spain*

13:35 - 14:00

Multidisciplinary Symposium on Systemic Mastocytosis:

When complexity calls for a shared vision: a symposium among experts on diagnosis and management

Dr. David González de Olano, *Hospital Universitario Ramón y Cajal. Madrid, Spain*

Dr. Miguel Piris-Villaespesa, *Hospital Universitario Ramón y Cajal. Madrid, Spain*

14:00 - 14:15

Discussion

14:40 - 15:30

SESSION 3

Daily challenges and complex decisions in Acute Leukemia

Chairs:

Dr. Ángela Figuera, *Hospital de La Princesa. Madrid, Spain*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid-Hospiten, Spain*

Dr. Joaquín Sánchez, *Hospital Universitario Reina Sofía. Córdoba, Spain*

14:40 - 15:00

Hematologic neoplasms arising from donor cells

Dr. Andrés Jerez, *Hospital Universitario Vall d'Hebron. Barcelona, Spain*

15:00 - 15:15

Clinical case

Late IDH1-mutated isolated extramedullary relapse in myelodysplasia-related acute myeloid leukemia secondary to primary myelofibrosis: triplet therapy followed by second allogeneic hematopoietic stem cell transplantation

Dr. María Gaspar Regaño, *Hospital Clínico Universitario Lozano Blesa, Zaragoza*

15:15 - 15:30

Discussion

15:30 - 16:45

SESSION 4

AML-1 intensive chemotherapy vs. VEN+AZA

Chairs:

Dr. Jordi Esteve, *Hospital Clinic de Barcelona, Spain*

Dr. Anne Louise Tølbøll Sørensen, *Rigshospitalet Copenhagen University, Denmark*

Dr. María Marta Rivas, *Hospital Universitario Austral. Buenos Aires, Argentina*

15:30 - 15:50

The clue is in the details: the Paradigm study - design, patients and beyond

Dr. Alexander Perl, *Abramson Cancer Center – University of Pennsylvania. Philadelphia, USA*

15:50 - 16:10

Intensive QT

Dr. Eduardo Rodríguez Arbolí, *Hospital Universitario Virgen del Rocío. Sevilla, Spain*

16:10 - 16:30

Ven+AzA

Dr. Irene Sánchez, *Hospital Universitario La Paz. Madrid, Spain*

16:30 - 16:45

Discussion

15th

ANNUAL
ACUTE

LEUKEMIA
MEETING

IN PERSON
& VIRTUAL
EVENT

16:45 - 17:40

SESSION 5

MDS 2

Chairs:

Dr. Joaquín Sánchez, *Hospital Universitario Reina Sofía. Córdoba, Spain*
Dr. Claudia Sossa, *Complejo Médico Fundación Oftalmológica de Santander - Clínica Carlos Ardila Lulle (FOSCAL) Bucaramanga, Colombia*
Dr. Ana Alfonso, *Clínica Universidad de Navarra. Pamplona, Spain*

16:45 - 17:05

Bone marrow inflammation in MDS: a driver of clonal evolution and a therapeutic opportunity?

Dr. José Miguel Torregrosa, *Poitiers University Hospital, France*

17:05 - 17:25

Progress and future outlook in CMML

Dra. Blanca Xicoy, *ICO - Hospital Germans Trias i Pujol. Barcelona, Spain*

17:25 - 17:40

Discussion

17:40 - 18:10

Coffee break

18:10 - 19:35

SESSION 6

AML-2 IDH1

Chairs:

Dr. Margarida Coucelo, *Unidade Local de Saúde de Coimbra, Portugal*
Dr. Claudia Núñez-Torrón, *Hospital Universitario Infanta Sofía. Madrid, Spain*
Dr. María Marta Rivas, *Hospital Universitario Austral. Buenos Aires, Argentina*

18:10 - 18:25

BIG picture biology and early phase studies

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid-Hospiten, Spain*

18:25 - 18:40

The challenge of testing: isocitrate dehydrogenase-1 testing and first-line treatment in patients with European Leukaemia Network-defined acute myeloid leukaemia ineligible for intensive therapy: a multi-country survey

Dr. Alessandro Isidori, *Marche Nord Hospital. Pesaro, Italy*

18:40 - 18:55

Ivosidenib and azacitidine for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who have an IDH1 gene mutation and are not eligible for intensive chemotherapy: the ALIDHE trial

Dr. Susana Vives Polo, *ICO - Hospital Universitario Germans Trias i Pujol. Barcelona, Spain*

18:55 - 19:10

The impact of sequencing in AML

Dr. Rosa María Ayala, *Hospital Universitario 12 de Octubre. Madrid, Spain*

19:10 - 19:20

Clinical Case

Dr. Miguel López Esteban, *Hospital Universitario Gregorio Marañón. Madrid, Spain*

19:20 - 19:35

Discussion

19:35 - 20:30

SESSION 7

MDS 3

Chairs:

Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*

Dr. Mónica Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente. Concepción, Chile*

Dr. Virginia Abello, *Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center. Bogotá, Colombia*

19:35 - 19:55

New therapy for high-risk MDS in patients eligible for ALoTPH

Dr. Marina Díaz, *Hospital Clinic de Barcelona, Spain*

19:55 - 20:15

MRD in high-risk MDS: why we cannot simply copy the AML model

Dr. Guillermo García-Manero, *MD Anderson Cancer Center. Houston, USA*

20:15 - 20:30

Discussion

15th

ANNUAL
ACUTE

LEUKEMIA
MEETING

IN PERSON
& VIRTUAL
EVENT

Friday, 2nd of October, 2026

09:00 - 10:15

SESSION 8

AML combination therapies: total oral therapies and triplets on the horizon

Chairs:

Dr. Alessandro Isidori, *Marche Nord Hospital. Pesaro, Italy*

Dr. Carlos Plaza, *UEES Clinic y SOLCA. Guayaquil, Ecuador*

Dr. Claudia Núñez-Torrón, *Hospital Universitario Infanta Sofía. Madrid, Spain*

09:00 - 09:20

Moving toward total oral therapy

Dr. Gabriela Rodríguez Macías, *Hospital General Universitario Gregorio Marañón. Madrid, Spain*

09:20 - 09:40

Triplets: is this really low-intensity? Venetoclax-based therapies in the U.S.

Dr. Naval Daver, *MD Anderson Cancer Center. Houston, USA*

09:40 - 10:00

New therapeutic combinations in AML: moving beyond intensive chemotherapy

Dr. Hartmut Döhner, *Universitätsklinikum, Ulm. Ulm, Germany*

10:00 - 10:15

Discussion

10:15 - 10:40

Coffee break

10:40 - 11:20

SESSION 9

Colloquium

10:40 - 11:05

Daily challenges and complex decisions 2. FLT3 AML

Dr. Josefina Serrano, *Hospital Universitario Reina Sofía de Córdoba, Spain*

Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid-Hospiten, Spain*

11:05 - 11:20

Discussion

11:20 - 12:40

SESSION 10

Lymphoblastic Leukemia

Chairs:

Dr. Gilberto Barranco, *Hospital General de México, Mexico City*

Dr. Virginia Abello, *Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center Bogotá, Colombia*

Dr. Mayte Olave, *Hospital Clínico Universitario Lozano Blesa. Zaragoza, Spain*

11:20 - 11:40

Decisions based on MRD in ALL

Dr. Elias Jabbour, *MD Anderson Cancer Center. Houston, USA*

ALL colloquium

11:40 - 12:25

First-line treatment for B-ALL in adults: practical tips for day-to-day management

Dr. María Calbacho, *Hospital Universitario 12 de Octubre. Madrid, Spain*

Dr. Mónica Cabrero, *Hospital Clínico Universitario de Salamanca, Spain*

12:25 - 12:40

Discussion

12:40 - 13:40

SESSION 11

Augmented intelligence workshop

Chairs:

Dr. Carlos Jiménez-Chillón, *Hospital General Universitario Gregorio Marañón, Madrid, Spain*

Dr. Joaquín Sánchez, *Hospital Universitario Reina Sofía. Córdoba, Spain*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid-Hospiten, Spain*

Experts:

Miguel Ángel Sierra, *Account Manager - Healthcare & Life Science, Google*

César Tapias, *Data & AI Sales for Health Media Travel & Public, Google*

13:40 - 14:40

Lunch

15th

ANNUAL
ACUTE

LEUKEMIA
MEETING

IN PERSON
& VIRTUAL
EVENT

14:40 - 16:05

SESSION 12

AML-4 Post-Remission strategies to prevent relapse

Chairs:

Dr. Joana Brioso Infante, *Centro Hospitalar Universitário de Lisboa Norte, Portugal*
Dr. Mónica Alejandra Romero, *Hospital Clínico Regional Dr. Guillermo Grant Benavente, Concepción, Chile*
Dr. Mika Kontro, *University of Helsinki, Finland*

14:40 - 15:00

Impact of the redefinition of the MRD (ELN 2025)

Dr. Eva Barragán, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

15:00 - 15:45

Colloquium: MRD in AML from prognostic factor to actionable target

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid-Hospiten, Spain*
Dr. Joaquín Sánchez, *Hospital Universitario Reina Sofía, Córdoba, Spain*
Dr. Jordi Esteve, *Hospital Clinic de Barcelona, Spain*
Dr. Hartmut Döhner, *Universitätsklinikum Ulm, Germany*

15:45 - 16:05

Discussion

16:05 - 16:25

Coffee break

16:25 - 17:40

SESSION 13

AML-5 menin inhibitors

Chairs:

Dr. Mika Kontro, *University of Helsinki, Finland*
Dr. Anne Louise Tølbøll Sørensen, *Rigshospitalet Copenhagen University, Denmark*
Dr. Jordi Esteve, *Hospital Clinic Barcelona, Spain*

16:25 - 16:45

AML NPM1 and AML KMT2A rearrangement: biological basis, oncogenic potential, and mechanisms of resistance

Dr. Joaquín Sánchez, *Hospital Universitario Reina Sofía, Córdoba, Spain*

16:45 - 17:05

Menin inhibitors in KMT2A-rearranged, NPM1-mutated, and other HOX-expressing leukemias

Dr. Issa Ghayas, *MD Anderson Cancer Center, Houston, USA*

17:05 - 17:25

Menin inhibitors as monotherapy: from clinical trials to real-world practice

Dr. Cristina Papayannidis, *IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy*

17:25 - 17:40

Discussion

17:40 - 18:40

SESSION 14

AML-6 FLT3-mutated AML

Chairs:

Dr. Isolda Fernández, *Centro de Hematología Pavlovsky. Buenos Aires, Argentina*

Dr. Claudia Sossa, *Complejo Médico Fundación Oftalmológica de Santander - Clínica Carlos Ardila Lulle (FOSCAL). Bucaramanga, Colombia*

17:40 - 18:20

Colloquium

FLT3-mutated AML (low-intensity treatment vs. intensive chemotherapy, transplant for all?)

Dr. Jordi Esteve, *Hospital Clinic Barcelona, Spain*

Dr. Alessandro Isidori, *Marche Nord Hospital. Pesaro, Italy*

Dr. Naval Daver, *MD Anderson Cancer Center. Houston, USA*

18:20 - 18:40

Discussion

18:40 - 18:50

Closing and farewell



01st
& 02nd
OCTOBER
2026

Sponsors

PLATINUM



GOLD



SILVER



BASIC



Organized by

MDAnderson
Cancer Center
Fundación • España

 Hospiten

MDAnderson
Cancer Center
Madrid • España

 Hospiten

Accreditation

*Credits requested from the Continuing Education Commission
of Health Professions of the Community of Madrid*



The MedTech Europe Code of Ethical Business Practice regulates all aspects of the industry's relationship with Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs), such as company-organized events, arrangements with consultants, research and financial support to medical education, amongst others. It also introduces an independent enforcement mechanism.

Such a Code is key as it aims at ensuring that all interactions between companies and Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs), such as hospitals and clinics, are ethical and professional at all times, and beyond criticism to maintain the trust of regulators, and – most important of all – patients. MedTech Europe is committed to promote legitimate and ethical business practices, encouraging responsible and ethical interactions with HCPs and HCOs. 15th Annual Acute Leukemia Meeting has been found COMPLIANT in accordance with the principles and standards set out in the MedTech Europe Code of Ethical Business Practice (event ref. EMT-26-11071)

Auspice

With the scientific endorsement of



Sociedad Española de
Hematología y Hemoterapia

Venue

MD Anderson Cancer Center Spain - Hospiten Foundation Auditorium
C/ Arturo Soria, 270, 28033, Madrid



Technical Secretariat
Tel. (+34) 676 853 540
e-mail: cursoleucemia@doctaforum.com
www.MDAndersonHospiten.es/CursoLeucemia